Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.26, $0.12 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $181.89 million versus the consensus estimate of $198.05 million.

GUIDANCE:

Corcept Therapeutics sees FY2025 revenue of $900-950 million, versus the consensus of $855.1 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.